Evaxion Biotech A/S [EVAX] fell -47.29% so far this year. What now?

0


Evaxion Biotech A/S. [NASDAQ: EVAX] The price rose by 22.63 percent to reach $0.43. Company report on September 21 2022 This important milestone has been reached in the customized cancer therapy EVX-01 from Evaxion Biotech.


Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now .

sponsored by


Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or “the Company”), a clinical-stage biotech company specializing in developing AI-based immunotherapies, has reached a milestone today which announced that it has registered its first patient It is in Phase 2B of the global clinical trial of EVX-01, the company’s dedicated cancer therapy for treating skin cancer.

In the company’s Phase 1 2B clinical trial, Evaxion is evaluating the efficacy and safety of EVX-01 in adults with metastatic melanoma. The trial is being conducted globally at clinical sites across the United States, Europe and Australia in collaboration with Merck & Co. , Inc. , which supplies the trial PD-1 inhibitor, KEYTRUDA®.

46115043 shares were traded in the last session while the average daily trading volume was 31.49 thousand shares. Shares of Evaxion Biotech A/S reached a high of $3,5199 and fell to $2.15 to close at $2.33 in the last session.

EVAX’s 1-year forecast is for a potential high of 84.97. The average equity rating of EVAX stock is currently 1.30, and it is trading near a bullish pattern in the stock market.

Teacher’s opinion on Evaxion Biotech A/S [EVAX]:

Based on careful, fact-backed analysis by Wall Street experts, the current consensus on a target price for EVAX shares is $15.50 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus for EVAX stock is a set recommendation at 1.30. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.

The Average True Range (ATR) for Evaxion Biotech A/S was set at 0.28 and the price-to-book ratio for the last quarter was 2.74, with the price-to-cash per share for the same quarter set at 1.06.

EVAX stock performance analysis:

Evaxion Biotech A/S. [EVAX] Profited in the green at the end of last week, gained a positive trend and rose by 13.66. With this latest performance, EVAX shares are down -13.70% over the past four-week period, and have also fallen -28.31% over the past six months – not to mention a -71.27% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for EVAX stock for the last two week period is set at 52.50, with the RSI for the last one traded at 59.71, and the three-week RSI is set at 49.96 for Evaxion Biotech A/S [EVAX]. The current moving average for the last 50 trading days of this stock is 2.5400, while it was recorded at 2.0600 for the last trading week, and 2.8500 for the last 200 days.

An insight into the basics of Evaxion Biotech A/S:

Evaxion Biotech A/S’s liquidity data is also interesting, with the quick ratio at 6.50 and the current ratio at 6.50.

Evaxion Biotech A/S. [EVAX] Insider position details

Currently, approximately $1 million, or 1.00% of EVAX’s stock, is in the hands of institutional investors. The three largest corporate owners of EVAX stock are: TELEMETRY INVESTMENTS, LLC with ownership of 122,000, which is approximately -27.698% of the company’s market capitalization and approximately 42.47% of the total corporate ownership; CITADEL ADVISORS LLC, which owns 83.586 shares of stock with an approximate value of $0.2 million in EVAX stock; and RENAISSANCE TECHNOLOGIES LLC, with $27000.0 in EVAX stock with nearly new ownership of the company’s market value.

Positions in Evaxion Biotech A/S Stocks Held by Institutional Investors Increased at the End of August and at the Time of the August Report as 3 Institutional Owners Consolidated Their Position in Evaxion Biotech A/S [NASDAQ:EVAX] About 82,536 shares. In addition, 9 investors reduced their positions by 534,097 shares, while 2 investors kept 389,669 shares. The said changes put institutional holdings at 226,964 shares, according to the latest report from the Securities and Exchange Commission. EVAX 2 shares had new institutional investment with a total of 11,700 shares, while 5 institutional investors sold 482.192 shares transactions during the same period.

Leave A Reply

Your email address will not be published.